

## **Randomized trials on non-pharmaceutical interventions for COVID-19 as of August 2021: a meta-epidemiological analysis**

Julian Hirt<sup>1,2</sup>, Perrine Janiaud<sup>1</sup>, Lars G. Hemkens<sup>1,3,4</sup>

<sup>1</sup> Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland

<sup>2</sup> International Graduate Academy, Institute for Health and Nursing Science, Medical Faculty, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany

<sup>3</sup> Meta-Research Innovation Center at Stanford (METRICS), Stanford University, Stanford, CA, USA,

<sup>4</sup> Meta-Research Innovation Center Berlin (METRIC-B), Berlin Institute of Health, Berlin, Germany

Corresponding author: Lars G. Hemkens, MD, MPH, Department of Clinical Research, University Hospital Basel, Spitalstrasse 12, CH-4031 Basel, Switzerland, Phone: +41 61 265 3100, email: [lars.hemkens@usb.ch](mailto:lars.hemkens@usb.ch)

### **ORCID**

Julian Hirt: 0000-0001-6589-3936

Perrine Janiaud: 0000-0001-7684-8014

Lars G. Hemkens: 0000-0002-3444-1432

### **Declarations**

Availability of data and materials: All data generated or analyzed during this study are included in this publication.

Ethical approval: Not necessary for this study.

Competing interests: None declared.

Funding: The COVID-evidence project is supported by the Swiss National Science Foundation, project ID 31CA30\_196190.

Role of the Funder: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

Authors' contributions: The authors had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: All authors.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: All authors.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Hirt.

Obtained funding: Hemkens.

Administrative, technical, or material support: n/a.

Supervision: Hemkens, Janiaud.

Word count of the manuscript text: 1137

## **Abstract**

**Background:** Numerous non-pharmaceutical interventions (NPIs) were taken worldwide to contain the spread of the COVID-19 pandemic. We aimed at providing an overview of randomized trials assessing NPIs to prevent COVID-19.

**Methods:** We included all randomized trials assessing NPIs to prevent COVID-19 in any country and setting registered in ClinicalTrials.gov and the World Health Organization International Clinical Trials Registry Platform using the COVID-evidence platform (until 17 August 2021). We searched for corresponding publications in MEDLINE/PubMed, Google Scholar, the Living Overview of Evidence platform (L-OVE), and the Cochrane COVID-19 registry as well as for results posted in registries.

**Results:** We identified 41 randomized trials. Of them, 11 were completed (26.8%) including 7 with published results. The 41 trials planned to recruit a median of 1,700 participants (IQR, 588 to 9,500, range 30 to 35,256,399) with a median planned duration of 8 months (IQR, 3 to 14, range 1 to 24). Most came from the United States (n=11, 26.8%). The trials mostly assessed protective equipment (n=11, 26.8%), COVID-19-related information and education programs (n=9, 22.0%), access to mass events under specific safety measures (n=5, 12.2%), testing and screening strategies (n=5, 12.2%), and hygiene management (n=5, 12.2%).

**Conclusions:** Worldwide, 41 randomized trials assessing NPIs have been initiated with published results available to inform policy decisions for only 7 of them. A long-term research agenda including behavioral, environmental, social, and systems level interventions is urgently needed to guide policies and practices in the current and future public health emergencies.

## **Introduction**

Numerous non-pharmaceutical interventions (NPIs) were taken worldwide to contain the COVID-19 pandemic.<sup>1</sup> NPIs are considered crucial to prevent infections, in particular for non-vaccinated populations.<sup>2</sup> Such interventions during COVID-19 include drastic social distancing and lockdown measures impacting billions of people. The need for randomized evidence on NPIs has been highlighted on numerous occasions<sup>3-5</sup>. However, no randomized trials assessing NPIs were initiated early in the pandemic<sup>6</sup> and it is likely their number have remained sparse.<sup>7-9</sup> We aimed to provide a systematic overview of the research agenda of randomized trials assessing NPIs to prevent COVID-19.

## **Methods**

A meta-epidemiological analysis was performed to collect the current trials on NPIs and to summarize their status and characteristics. We did not register this study or published a specific study protocol. We adapted PRISMA 2020 to provide a comprehensive study report, where applicable.<sup>10</sup>

### ***Eligibility criteria***

This meta-epidemiological analysis included all registered randomized trials assessing NPIs to prevent COVID-19 in any country and setting. We considered any NPIs as single measures or in combination involving, for example, information and education interventions, protective equipment, disinfection, social distancing, isolation, quarantine, testing, or community-wide containment strategies. We excluded interventions based on drugs, biologicals, vaccines, herbals, traditional medicine, and homeopathy. Trials assessing NPIs without any health outcome related to SARS-CoV-2-infections were excluded (e.g., interventions aiming to improve vaccination rates).

### ***Search and selection of trials***

We searched the COVID-evidence platform ([www.covid-evidence.org](http://www.covid-evidence.org)) for eligible trials as of 17 August 2021. COVID-evidence is a freely available continuously updated database that contains information about worldwide planned, ongoing, and completed randomized trials on any intervention to treat or prevent SARS-CoV-2-infections. Trials registered in ClinicalTrials.gov and the World Health Organization International Clinical Trials Registry Platform (ICTRP) are retrieved on a weekly basis. COVID-evidence uses a multimethod approach combining peer-reviewed search strategies of study registries, continuous automated extraction of search results, automated classifications combined with manual screening and data extraction (details on the methodology are published elsewhere<sup>11</sup>). For all NPI eligible trials identified in COVID-evidence, we searched for corresponding publications (peer-reviewed and preprints) in MEDLINE/PubMed, Google Scholar, the Living Overview of Evidence platform (L-OVE), and the Cochrane COVID-19 registry using trial registration numbers (until 19 August 2021). We also recorded if trial results were reported in the registries. All searches

and the selection of trials were done by one researcher (JH or PJ). Unclear cases were discussed and resolved within the study team (JH, PJ, LGH).

### ***Data extraction***

One researcher (JH) extracted data on trial status, start to end date, country, setting, number of enrolled individuals and clusters, topic (details on NPIs and characteristics of the population), and design features (randomization unit, number of arms, outcome measurement). Extractions were tabulated and verified by two other researchers (PJ, LGH).

### ***Data analysis***

Descriptive statistics using numbers and percentages were used. We used R (version 4.1).

### **Results**

We identified 41 eligible randomized trials (Figure; Table). As of August 2021, 11 trials were completed (26.8%) including 7 with published results, 17 ongoing (41.5%), 11 not yet recruiting (26.8%), and 2 terminated early or withdrawn (5.9%). Most came from the United States (n=11, 26.8%), United Kingdom (n=4, 9.8%), and France (n=4, 9.8%). Of note, none of the completed and terminated trials had made their results available on the registries.

The types of NPIs were diverse. Of the 41 trials, 11 trials (26.8%) assessed protective equipment such as various masks, face shields or goggles; 9 trials (22.0%) assessed diverse COVID-19-related information and education programs (e.g., text messages, newsfeeds, personalized health education, Facebook advertisements, nurse-led home visits); 5 trials (12.2%) assessed the impact of attending a musical mass event/concert under specific safety measures; 5 trials (12.2%) assessed diverse testing and screening strategies in nursing homes, schools, universities, and the emergency department; 5 trials (12.2%) assessed multicomponent behavioral interventions on hygiene management in the community. The other 6 trials assessed access to a fitness center, school opening, special housing of homeless individuals, direct income support for individuals with COVID-19-related financial disruptions, yoga sessions for health care professionals, and COVID-19-related symptom tracking in outpatients with cancer.

The trials planned to recruit a median of 1,700 participants (IQR, 588 to 9,500, range 30 to 35,256,399) with a median planned duration of 8 months (IQR, 3 to 14, range 1 to 24). The largest trial assessed the impact of Facebook advertisements to prevent traveling and family reunions during Thanksgiving and Christmas with >35 million participants<sup>12</sup>, the shortest trial assessed the audience infection rate 8 days after an indoor music event.<sup>13</sup> A typical randomized trial on NPIs randomly allocated individuals (n=23, 56.1%), rather than clusters (n=18, 43.9%), to two comparison groups (n=38, 92.7%) and assessed a COVID-19-related primary outcome (n=33, 80.5%) that was laboratory-confirmed (n=33, 80.5%).

## **Discussion**

Worldwide, 41 randomized trials assessing NPIs have been initiated with published results available to inform policy decisions for only 7 of them. This is a tiny fraction of more than 4000 randomized trials on COVID-19 registered globally as of August 2021.<sup>11</sup> Given the unprecedented public health impact worldwide and the wide debates about benefits and harms of NPIs, this number seems disproportionate in light of other interventions that have been the focus of much more evaluation with randomized trials. For example, over 300 randomized trials included the highly debated hydroxychloroquine in their intervention arm<sup>14</sup> which has been found to be associated with increased mortality in COVID-19 patients.<sup>15</sup>

The list of available treatments for COVID-19 is limited<sup>16,17</sup> and with vaccination rates plateauing in many countries<sup>18</sup>, NPIs and their effectiveness will remain a central debate. Our analysis clearly indicates that randomized trials are generally feasible to assess the benefits and harms of NPIs during a pandemic situation, in a very short time using the most reliable method to provide reliable evidence for optimal health policy decision making. The World Health Organization (WHO) is committed to improving the evidence base on effectiveness of public health and social measures<sup>19</sup>, and this overview may inform further developments in this important area of evidence generation.

This study is limited as our sample relies on accurate trial registration and reporting. We cannot exclude that some NPI randomized trials might have been missed because they were not registered, outcomes related to SARS-CoV-2-infections were incorrectly or not reported in the registries, or because of our single-reviewer screening approach. However, it is unlikely that we have been unaware of pertinent results of further NPI trials, given their substantial impact on current debates and scarcity of the evidence.

## **Conclusions**

Overall, during the first 18 months of the pandemic, the worldwide clinical research agenda failed to provide urgently needed evidence determining best strategies to prevent COVID-19 in schools, workplaces, nursing homes and other settings substantially affected. A long-term research agenda including behavioral, environmental, social, and systems level interventions is urgently needed to guide policies and practices in the current and future public health emergencies.

## References

1. World Health Organization. Overview of public health and social measures in the context of COVID-19: Interim guidance. Accessed July 25, 2021.  
<https://www.who.int/publications/i/item/overview-of-public-health-and-social-measures-in-the-context-of-covid-19>
2. Doroshenko A. The Combined Effect of Vaccination and Nonpharmaceutical Public Health Interventions-Ending the COVID-19 Pandemic. *JAMA Netw Open*. 2021;4(6):e2111675.  
doi:10.1001/jamanetworkopen.2021.11675
3. Cristea IA, Naudet F, Ioannidis JPA. Preserving equipoise and performing randomised trials for COVID-19 social distancing interventions. *Epidemiol Psychiatr Sci*. 2020;29:e184.  
doi:10.1017/S2045796020000992
4. Fretheim A, Flatø M, Steens A, et al. COVID-19: we need randomised trials of school closures. *J Epidemiol Community Health*. 2020;74(12):1078-1079. doi:10.1136/jech-2020-214262
5. Ioannidis JPA. A fiasco in the making? As the coronavirus pandemic takes hold, we are making decisions without reliable data. *STAT*. Published 2020. Accessed August 19, 2021.  
<https://www.statnews.com/2020/03/17/a-fiasco-in-the-making-as-the-coronavirus-pandemic-takes-hold-we-are-making-decisions-without-reliable-data/>.
6. Janiaud P, Axfors C, van't Hooft J, et al. The worldwide clinical trial research response to the COVID-19 pandemic - the first 100 days [version 2; peer review: 2 approved]. *F1000Res*. 2020;9:1193. doi:10.12688/f1000research.26707.2
7. Burns J, Movsisyan A, Stratil JM, et al. International travel-related control measures to contain the COVID-19 pandemic: a rapid review. *Cochrane Database Syst Rev*. 2021;3:CD013717.  
doi:10.1002/14651858.CD013717.pub2
8. Nussbaumer-Streit B, Mayr V, Dobrescu AI, et al. Quarantine alone or in combination with other public health measures to control COVID-19: a rapid review. *Cochrane Database Syst Rev*. 2020;9:CD013574. doi:10.1002/14651858.CD013574.pub2
9. Regmi K, Lwin CM. Impact of non-pharmaceutical interventions for reducing transmission of COVID-19: a systematic review and meta-analysis protocol. *BMJ Open*. 2020;10(10):e041383.  
doi:10.1136/bmjopen-2020-041383
10. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. 2021;372:n71. doi:10.1136/bmj.n71
11. COVID-evidence Database. Planned, ongoing and completed trials to treat and prevent COVID-19. Published July 27, 2021. Accessed July 27, 2021. <https://covid-evidence.org/database>
12. Breza E, Stanford FC, Alsan M, et al. Doctors' and Nurses' Social Media Ads Reduced Holiday Travel and COVID-19 infections: A cluster randomized controlled trial in 13 States: Preprint;2021. doi:10.1101/2021.06.23.21259402

13. Revollo B, Blanco I, Soler P, et al. Same-day SARS-CoV-2 antigen test screening in an indoor mass-gathering live music event: a randomised controlled trial. *The Lancet Infectious Diseases*. 2021;Article in Press. doi:10.1016/S1473-3099(21)00268-1
14. Janiaud P, Hemkens LG, Ioannidis JP. Challenges and lessons learned from Covid-19 trials – should we be doing clinical trials differently? *Canadian Journal of Cardiology*. 2021;Article in Press. doi:10.1016/j.cjca.2021.05.009
15. Axfors C, Schmitt AM, Janiaud P, et al. Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. *Nat Commun*. 2021;12:2349. doi:10.1038/s41467-021-22446-z
16. U.S. Food and Drug Administration. Emergency Use Authorization: Coronavirus Disease 2019 (COVID-19) EUA Information. Accessed August 19, 2021. <https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#covid19euas>
17. European Medicines Agency. Treatments and vaccines for COVID-19. Published August 19, 2021. Accessed August 19, 2021. <https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines-covid-19>
18. Blamont M, Erman M, Lubell M. Vaccination burnout?: Delta variant spurs countries to speed up shots. Published 2021. Accessed August 19, 2021. <https://graphics.reuters.com/HEALTH-CORONAVIRUS/VACCINATION/xklvyxrdgpg/>.
19. World Health Organization. Director-General's opening remarks at the media briefing on COVID-19 – 14 June 2021. Published August 4, 2021. Accessed August 17, 2021. <https://www.who.int/director-general/speeches/detail/director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-14-june-2021>
20. Janiaud P, Axfors C, Saccilotto R, Schmitt AM, Hirt J, Hemkens LG. COVID-evidence: a living database of trials on interventions for COVID-19. Accessed May 31, 2021. <https://osf.io/gehfx/>

Table. Characteristics of all 41 randomized trials on non-pharmaceutical interventions to prevent COVID-19 as of August 2021

Trial ID	Start to end date	Country	Setting	N individuals (clusters <sup>a</sup> )	Topic
<b>Completed (n=11)</b>					
<b>Completed with published results (n=7)</b>					
ChiCTR2000030317	2020-02 to 2020-04	China	Hospital	320	Self-made gastroscope mask for patients (18-79 years) during gastroscopy
NCT04337541	2020-04 to 2020-06	Denmark	Community	6,024	Face masks for adults (≥18 years)
NCT04406909 <sup>b</sup>	2020-05 to 2020-06	Norway	Community	3,764	Access to indoor fitness center for adults (18-64 years)
CTRI/2020/07/026667	2020-09 to 2020-11	India	Hospital	280	Pranayama yoga vs. general fitness practices (e.g., walking, jogging, running) for health care professionals (18-65 years) with COVID-19 duties
NCT04644328 <sup>b,c</sup>	2020-11 to 2021-01	USA	Community	11,954,109; 23,302,290 (820; 767)	Facebook ads for adults (≥18 years) on limiting travel, social distancing, and mask-wearing before Thanksgiving and Christmas
NCT04668625	2020-12 to 2012-12	Spain	Community	1,047	Access to an indoor music event for adults (18-59 years)
ISRCTN18100261 <sup>b</sup>	2021-04 to 2021-06	United Kingdom	School	200,000 (201)	Daily testing of contact cases vs. isolating contacts of school staff and students (secondary school and further education college)
<b>Completed without published results (n=4)</b>					
ISRCTN14602359	2020-03 to 2021-03	United Kingdom	GP practice	n.r. (3292)	Behavior intervention on how to reduce the spread of infection using Germ Defence (interactive website) for adults (≥18 years)
NCT04630054	2020-11 to 2021-02	Bangladesh	Community	450,000 (600)	Masks and behavior change communication details for adults (≥18 years)
NCT04647305	2021-01 to 2021-03	Colombia	Community	233	Closed face shield and surgical face mask vs. surgical face mask alone adults (≥18 years)
NCT04872075	2021-05 to 2021-06	France	Community	7,500	Access to an indoor music event for adults (18-45 years)
<b>Ongoing (n=17)</b>					
NCT04359264	2020-04 to 2020-05	Canada	Community	392	Income support of \$1000 to adults (≥18 years) suffering from COVID-19-related financial disruptions
NCT04296643	2020-04 to 2021-04	Canada, Israel	Hospital	576	Surgical masks vs. N95 respirator for nurses (≥18 years)
NCT04321928	2020-04 - 2021-08	Hungary	Community	7576	Personalized health education regarding lifestyle changes vs. general health education for adults (≥60 years)
NCT04644486	2020-04 to 2022-03	USA	Outpatient setting	300	COVID-19 symptom tracking in adult cancer patients (≥18 years)
NCT04471766	2020-07 to 2021-08	Guinea-Bissau	Community	40,000	Cloth face masks and information vs. information alone for children and adults (≥10 years)
ISRCTN69564614	2020-08 to 2022-01	United Kingdom	Community	1,200	Special housing for homeless individuals (no details concerning age) temporarily accommodated by the local authority
NCT04620798	2020-09 to 2020-12	USA	University	1,700	Immediate vs. delayed provision of COVID-19 antibody test results to students (≥18 years)
NCT04753645	2020-09 to 2021-05	Bangladesh	Community	3,840 (194)	Multicomponent hygiene intervention (handwashing stations, education, information) for children and adults (≥10 years)
PACTR202102616421588	2020-11 to 2021-07	Congo	Community	1,312 (121)	Multicomponent hygiene intervention (water, sanitation) for children and adults (without age limit)
NCT04565509	2020-11 to 2022-09	USA	School	2,500 (6)	Diverse messaging strategies to students, families, and school staff (5-90 years)
NCT04499391	2020-12 to 2022-07	USA	Nursing home	24,560 (200)	Multiple information course vs. unique information for staff (≥18 years)
NCT04726371	2021-01 to 2022-10	USA	Congregate care home	5,350 (400)	Tailored vs. generic information to care home staff and residents (≥18 years)
NCT04591015	2021-02 to 2021-08	USA	Outpatient setting	172	COVID-19 support messages for adults with diabetes (≥18 years)
NCT04830761	2021-03 to 2022-04	Switzerland	Community	710	Combination of diverse hygiene behavior change strategies (habit, motivation, social norms) for adults (≥18 years)
NCT04765475	2021-03 to 2022-09	USA	Community	600	Diverse behavioral strategies and COVID-19 symptom tracking for young adults (18-34 years) and older adults (≥65 years)
NCT04875520	2021-05 to 2023-03	USA	School	10,000 (16)	Weekly testing and symptomatic testing for SARS-CoV-2 vs. symptomatic testing alone of students and staff (≥4 years)
NCT04832919	2021-07 to 2022-05	USA	Community	810 (270)	Behavioral intervention, information, and offering of tests during bi-weekly home visits by nurses to households (≥10 years)
<b>Not yet recruiting (n=11)</b>					
NCT04453553	2020-07 to 2020-09	United Kingdom	Nursing home	n.r. (50)	Nasal swabs rapid testing of residents (without age limit)
PACTR202008485004797	2020-08 to 2021-03	South Africa	Community	720	Multicomponent infection mitigation intervention (WhatsApp-messages, protective equipment, disinfectants, lay health care worker support) vs. printed information on transmission for household contacts (≥12 years) of persons diagnosed with SARS-CoV-2
CTRI/2020/07/026796	2020-08 to n.r.	India	Community	10,000 (45)	Cotton face masks for adults (≥18 years)
CTRI/2020/12/029805	2020-12 to n.r.	India	Hospital	30	Ventilated goggles for health care workers inside COVID-19 intensive care unit (18-50 years)
NCT04756609	2021-02 to 2021-06	France	Hospital	104,000 (18)	Systematic offer of nurse-driven SARS-CoV-2 screening in adults (≥18 years) in the emergency department
NCT04823351	2021-04 to 2021-11	Switzerland	Nursing home	1,200 (n.r.)	FFP2 masks vs. surgical masks for nurses (≥18 years)
NCT04898127	2021-05 to 2021-12	Norway	Community	30,000	Access to a music event for adults (18-45 years)
NCT04868942	2021-05 to 2022-05	France	Community	4,500	Access to an indoor music event for students (18-29 years)
NCT04896970	2021-06 to 2021-07	France	Community	1,390	Access to an indoor music event for adults (18-59 years)
ACTRN12621000567820	2021-06 to 2022-10	Australia	Nursing home	400 (10)	Air-sterilisation strategy using ultraviolet light
NCT04979858	2021-08 to 2022-02	USA	University	200	Newly developed reusable form-fitting fabric mask vs. other masks for students (≥18 years) living on campus
<b>Withdrawn or terminated early (n=2)</b>					
ISRCTN44152751 (w)	2020-03 to 2020-09	Norway	School	238,125 (1905) <sup>d</sup>	School opening for 5-10 level pupils
NCT04377165 (t)	2020-05 to 2020-08	Australia	Nursing home	9000 (n.r.)	Newsfeed with reward system vs. newsfeed alone for healthcare workers (≥18 years)

Abbreviations: GP = General practitioner; N/n = Number; n.r. = Not reported; t = Terminated early; w = Withdrawn (trial did and will never start).

<sup>a</sup> For cluster randomized trials only.

<sup>b</sup> Published as preprint results as of 19 August 2021.

<sup>c</sup> Intervention was done twice (first on Thanksgiving, second on Christmas), numbers separated by semicolon for the first and second trial part.

<sup>d</sup> Planned sample size was calculated by the mean of the reported minimum and maximum for number of participants (116,750 to 359,500) and clusters (934 and 2,876).




Figure. Retrieval and trial selection process